# Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

> **NCT02267213** · PHASE2 · TERMINATED · sponsor: **Taiwan Liposome Company** · enrollment: 29 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Lipotecan

## Key facts

- **NCT ID:** NCT02267213
- **Lead sponsor:** Taiwan Liposome Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04-10
- **Primary completion:** 2015-07-09
- **Final completion:** 2015-07-09
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Current study design couldn't support futher development on this indication
- **Last updated:** 2019-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267213, "Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02267213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*